Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases
出版年份 2020 全文链接
标题
Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases
作者
关键词
-
出版物
Thoracic Cancer
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-07-13
DOI
10.1111/1759-7714.13557
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
- (2019) Lizza E.L. Hendriks et al. Journal of Thoracic Oncology
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017
- (2019) Natsuki Takano et al. LUNG CANCER
- Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
- (2018) Shirish M. Gadgeel et al. LUNG CANCER
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
- (2014) Chiara D’Antonio et al. Therapeutic Advances in Medical Oncology
- Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
- (2013) A. Ali et al. Current Oncology
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Trafficking of immune cells in the central nervous system
- (2010) Emma H. Wilson et al. JOURNAL OF CLINICAL INVESTIGATION
- Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer
- (2010) Martin J. Edelman et al. Journal of Thoracic Oncology
- Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma
- (2008) Ali G. Saad et al. CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started